Dianthus Therapeutics Inc. Total Liabilities
Dianthus Therapeutics Inc. total liabilities. Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has total liabilities worth $41.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Dianthus Therapeutics Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dianthus Therapeutics Inc. (2016–2025)
Total liabilities of Dianthus Therapeutics Inc. from 2016 to 2025. This chart illustrates how Dianthus Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Dianthus Therapeutics Inc. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Dianthus Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brookfield Infrastructure Corp
NYSE:BIPC
|
USA | $22.74 Billion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
China | CN¥42.31 Billion |
|
Bumrungrad Hospital Public Company Limited
BK:BH-R
|
Thailand | ฿4.80 Billion |
|
Shan XI Hua Yang Group New Energy Co Ltd
SHG:600348
|
China | CN¥50.81 Billion |
|
TFS Financial Corporation
NASDAQ:TFSL
|
USA | $16.12 Billion |
|
COSCO SHIPPING Specialized Carriers Co Ltd
SHG:600428
|
China | CN¥26.32 Billion |
|
AUTO1 Group SE
F:AG1
|
Germany | €2.08 Billion |
|
Chipbond Technology
TWO:6147
|
Taiwan | NT$8.60 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Dianthus Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dianthus Therapeutics Inc. asset portfolio.
Liquidity & Leverage Metrics
Dianthus Therapeutics Inc. Total Liabilities Ratios Explained
Dianthus Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dianthus Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual total liabilities of Dianthus Therapeutics Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.52 Million | +74.27% |
| 2024-12-31 | $21.53 Million | +104.38% |
| 2023-12-31 | $10.54 Million | +11.43% |
| 2022-12-31 | $9.45 Million | -45.23% |
| 2021-12-31 | $17.26 Million | -2.55% |
| 2020-12-31 | $17.71 Million | -12.83% |
| 2019-12-31 | $20.32 Million | +74.20% |
| 2018-12-31 | $11.66 Million | +181.63% |
| 2017-12-31 | $4.14 Million | +80.09% |
| 2016-12-31 | $2.30 Million | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more